EU Commission approves Gilead Trodelvy-Keytruda combo for first-line PD-L1+ metastatic TNBC

• European Commission granted marketing authorization for Trodelvy with Merck’s Keytruda in first-line metastatic triple-negative breast cancer with PD-L1 CPS ≥10.
• Decision expands Gilead’s Trodelvy use across PD-L1 status in Europe, including monotherapy for patients not eligible for PD-1 or PD-L1 inhibitors.
• Phase 3 ASCENT-04/KEYNOTE-D19 showed a 35% lower risk of disease progression or death versus standard chemotherapy with Keytruda.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260819110838) on August 24, 2026, and is solely responsible for the information contained therein.